penciclovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals bicyclic heterocycle compounds | 2079 | 39809-25-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The antiviral compound penciclovir has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 170 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 75 % | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 77 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.10 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 24, 1996 | FDA | DENCO ASSET |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D06BB06 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Antivirals |
| ATC | J05AB13 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
| FDA MoA | N0000020060 | DNA Polymerase Inhibitors |
| FDA EXT | N0000175459 | Nucleoside Analog |
| FDA EPC | N0000175468 | Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| CHEBI has role | CHEBI:36044 | antiviral drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Herpes labialis | indication | 1475003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.73 | acidic |
| pKa2 | 12.97 | acidic |
| pKa3 | 13.57 | acidic |
| pKa4 | 4.72 | Basic |
| pKa5 | 2.6 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| DNA polymerase catalytic subunit | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
| Thymidine kinase | Kinase | IC50 | 4.96 | CHEMBL | |||||
| Thymidine kinase | Kinase | IC50 | 4.07 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020992 | VUID |
| N0000148462 | NUI |
| D02124 | KEGG_DRUG |
| 97845-62-0 | SECONDARY_CAS_RN |
| 4020992 | VANDF |
| C0164815 | UMLSCUI |
| CHEBI:7956 | CHEBI |
| PE2 | PDB_CHEM_ID |
| CHEMBL1540 | ChEMBL_ID |
| DB00299 | DRUGBANK_ID |
| CHEMBL2079793 | ChEMBL_ID |
| C053539 | MESH_SUPPLEMENTAL_RECORD_UI |
| 135398748 | PUBCHEM_CID |
| 6437 | INN_ID |
| 359HUE8FJC | UNII |
| 216450 | RXNORM |
| 363014 | MMSL |
| 5242 | MMSL |
| 6064 | MMSL |
| 006111 | NDDF |
| 108918003 | SNOMEDCT_US |
| 386939003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Penciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3186 | CREAM | 10 mg | TOPICAL | ANDA | 25 sections |
| Penciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0896 | CREAM | 10 mg | TOPICAL | NDA authorized generic | 25 sections |
| Denavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-9720 | CREAM | 10 mg | TOPICAL | NDA | 26 sections |
| Penciclovir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-661 | CREAM | 10 mg | TOPICAL | ANDA | 26 sections |
| Denavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4956 | CREAM | 10 mg | TOPICAL | NDA | 20 sections |